39
Participants
Start Date
January 31, 1999
Primary Completion Date
August 31, 2008
Study Completion Date
August 31, 2008
Rituximab
Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Stanford University Medical Center, Stanford
Stanford University School of Medicine, Stanford
Collaborators (1)
Genentech, Inc.
INDUSTRY
Ranjana Advani
OTHER